Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma

Urologic Clinics of North America

Volumn 39, Issue 2, 2012, Pages 211-231

  Kenney, Patrick A ^a   Wood, Christopher G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Angiogenesis inhibitor; Cytoreductive nephrectomy; Immunotherapy; Neoadjuvant therapy; Renal cell carcinoma; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BCG VACCINE; BEVACIZUMAB; CANCER VACCINE; CARBONATE DEHYDRATASE IX; CYTOKINE; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GIRENTUXIMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROXYPROGESTERONE ACETATE; MONOCLONAL ANTIBODY; PAZOPANIB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; SURVIVIN; TEMSIROLIMUS; THALIDOMIDE; VIMENTIN; VITESPEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL OBSERVATION; CYTOREDUCTIVE SURGERY; DENDRITIC CELL; DISEASE MARKER; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; HUMAN; INTEGRATIVE MEDICINE; KIDNEY ARTERY EMBOLIZATION; KIDNEY CARCINOMA; KIDNEY SURGERY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NOMENCLATURE; PARTIAL NEPHRECTOMY; PATIENT SELECTION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; WOUND DEHISCENCE; WOUND INFECTION;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84859508939     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2012.01.005     Document Type: Review

References (130)

1. Howlader N, Noone A, Kraphcho M, et al, editors. SEER cancer statistics review, 1975-2008. 2011. Available at: Accessed December 7, 2011. http://seer.cancer.gov/csr/1975_2008/.
2. Bex A., Jonasch E., Kirkali Z., et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol 2010, 58:819-828.
3. Crispen P.L., Boorjian S.A., Lohse C.M., et al. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer 2008, 113:450-460.
4. Jacobsohn K., Wood C. Adjuvant therapy for renal cell carcinoma. Semin Oncol 2006, 33:576-582.
5. Wood C.G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2007, 13:697s-702s.
6. Kattan M.W., Reuter V., Motzer R.J., et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001, 166:63-67.
7. Sorbellini M., Kattan M.W., Snyder M.E., et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005, 173:48-51.
8. Leibovich B.C., Blute M.L., Cheville J.C., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97:1663-1671.
9. Zisman A. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002, 20:4559-4566.
10. Levy D.A., Slaton J.W., Swanson D.A., et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998, 159:1163-1167.
11. Klatte T., Lam J.S., Shuch B., et al. Surveillance for renal cell carcinoma: why and how? When and how often?. Urol Oncol 2008, 26:550-554.
12. Patard J.J. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004, 22:3316-3322.
13. Lane B.R., Kattan M.W. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am 2008, 35:613-625. vii.
14. Cindolo L., Patard J.-J., Chiodini P., et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 2005, 104:1362-1371.
15. Cindolo L., la Taille de A., Messina G., et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 2003, 92:901-905.
16. Yaycioglu O., Roberts W.W., Chan T., et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 2001, 58:141-145.
17. Raj G.V., Thompson R.H., Leibovich B.C., et al. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol 2008, 179:2146-2151. [discussion: 2151].
18. Smaldone M.C., Fung C., Uzzo R.G., et al. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. Hematol Oncol Clin North Am 2011, 25:765-791.
19. Kim H.L. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004, 10:5464-5471.
20. Klatte T., Seligson D.B., LaRochelle J., et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 2009, 18:894-900.
21. Parker A.S., Leibovich B.C., Lohse C.M., et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009, 115:2092-2103.
22. Choueiri M., Tannir N., Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol 2011, 6:144-150.
23. Aref I., Bociek R.G., Salhani D. Is post-operative radiation for renal cell carcinoma justified?. Radiother Oncol 1997, 43:155-157.
24. Finney R. The value of radiotherapy in the treatment of hypernephroma-a clinical trial. BJU Int 1973, 45:258-269.
25. Kjaer M., Frederiksen P. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen renal cancer study group. Int J Radiat Oncol Biol Phys 1987, 13:665-672.
26. Lam J.S., Belldegrun A.S., Figlin R.A. Adjuvant treatment for renal cell carcinoma. Expert Opin Pharmacother 2006, 7:706-720.
27. Pizzocaro G., Piva L., Di Fronzo G., et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 1987, 138:1379-1381.
28. Shimabukuro T., Naito K. Tumor-infiltrating lymphocytes derived from human renal cell carcinoma: clonal analysis of its characteristics. Int J Urol 2008, 15:241-244.
29. Kradin R., Lazarus D., Dubinett S., et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989, 333:577-580.
30. Finke J., Tubbs R., Connelly B., et al. Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann N Y Acad Sci 1988, 532:387-394.
31. Vogelzang N.J., Priest E.R., Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992, 148:1247-1248.
32. Sánchez-Ortiz R.F., Tannir N., Ahrar K., et al. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine?. J Urol 2003, 170:178-179.
33. Fujikawa K., Matsui Y., Miura K., et al. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy. J Urol 2000, 164:673-675.
34. Dadian G., Riches P.G., Henderson D.C., et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol 1994, 74:15-22.
35. Montie J.E., Straffon R.A., Deodhar S.D., et al. In vitro assessment of cell-mediated immunity in patients with renal cell carcinoma. J Urol 1976, 115:239-242.
36. Rayman P. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 2004, 10:6360S-6366S.
37. Arya M., Chao D., Patel H.R. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer. Nat Clin Pract Oncol 2004, 1:32-38.
38. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005, 23:133-141.
39. Lam J., Leppert J., Belldegrun A. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005, 23:202-212.
40. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999, 353:14-17.
41. Pyrhönen S., Salminen E., Ruutu M., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999, 17:2859-2867.
42. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688-696.
43. Messing E.M., Manola J., Wilding G., et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003, 21:1214-1222.
44. Pizzocaro G., Piva L., Colavita M., et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001, 19:425-431.
45. Clark J.I., Atkins M.B., Urba W.J., et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003, 21:3133-3140.
46. Atzpodien J., Schmitt E., Gertenbach U., et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005, 92:843-846.
47. Galligioni E., Quaia M., Merlo A., et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study. Cancer 1996, 77:2560-2566.
48. Jocham D., Richter A., Hoffmann L., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004, 363:594-599.
49. Rassweiler J. Re: ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Eur Urol 2012, 61:219-220.
50. Doehn C., Richter A., Theodor R.A., et al. An adjuvant vaccination with Reniale prolongs survival in patients with renal cell carcinoma following radical nephrectomy. Eur Urol Suppl 2006, 5:286. Available at:, Accessed December 7, 2011. http://www.sciencedirect.com/science/article/pii/S0302283811011201.
51. May M., Brookman-May S., Hoschke B., et al. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother 2010, 59:687-695.
52. Wood C., Srivastava P., Bukowski R., et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008, 372:145-154.
53. Daliani D.D., Papandreou C.N., Thall P.F., et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 2002, 95:758-765.
54. Margulis V., Matin S.F., Tannir N., et al. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 2009, 73:337-341.
55. Plimack E.R., Tannir N., Lin E., et al. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer 2009, 115:1859-1866.
56. Ebos J.M.L., Lee C.R., Cruz-Munoz W., et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
57. Pàez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
58. Arnold K. WILEX AG press release: ARISER Independent Data Monitoring Committee (IDMC) recommends conducting the final analysis of the pivotal Phase III trial with RENCAREX. 2011. Available at: Accessed December 7, 2011. http://www.wilex.de/press-investors/announcements/press-releases/21112011-2/.
59. Escudier B., Eisen T., Stadler W. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
60. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
61. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
62. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
63. Kjaer M., Iversen P., Hvidt V., et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 1987, 21(4):285-289.
64. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2005, 2. Advanced Bladder Cancer Overview Collaboration, CD005246.
65. Bex A., Horenblas S., Meinhardt W., et al. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol 2002, 42:570-574. [discussion: 575-6].
66. Jonasch E., Tannir N.M. Targeted therapy for locally advanced renal cell carcinoma. Target Oncol 2010, 5:113-118.
67. Zielinski H., Szmigielski S., Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol 2000, 23:6-12.
68. Kalman D., Varenhorst E. The role of arterial embolization in renal cell carcinoma. Scand J Urol Nephrol 1999, 33:162-170.
69. Mohr S.J., Whitesel J.A. Spontaneous regression of renal cell carcinoma metastases after preoperative embolization of primary tumor and subsequent nephrectomy. Urology 1979, 14:5-8.
70. Swanson D.A., Johnson D.E., Eschenbach von A.C., et al. Angioinfarction plus nephrectomy for metastatic renal cell carcinoma-an update. J Urol 1983, 130:449-452.
71. Bakke A., Göthlin J.H., Haukaas S.A., et al. Augmentation of natural killer cell activity after arterial embolization of renal carcinomas. Cancer Res 1982, 42:3880-3883.
72. Nakano H., Nihira H., Toge T. Treatment of renal cancer patients by transcatheter embolization and its effects on lymphocyte proliferative responses. J Urol 1983, 130:24-27.
73. Johnson G., Kalland T. Enhancement of mouse natural killer cell activity after dearterialization of experimental renal tumors. J Urol 1984, 132:1250-1253.
74. Thomas A.A., Rini B.I., Lane B.R., et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009, 181:518-523. [discussion: 523].
75. Robert G., Gabbay G., Bram R., et al. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol 2009, 55:1477-1480.
76. Van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 2008, 14:2431-2436.
77. Desar I.M., van Herpen C.M., van Laarhoven H.W., et al. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009, 35:309-321.
78. Jonasch E., Wood C.G., Matin S.F., et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:4076-4081.
79. Cowey C.L., Amin C., Pruthi R.S., et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010, 28:1502-1507.
80. Abel E.J., Culp S.H., Tannir N.M., et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011, 59:10-15.
81. Ficarra V., Novara G. Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma. Nat Rev Urol 2010, 7:63-64.
82. Bijol V., Mendez G.P., Hurwitz S., et al. Evaluation of the nonneoplastic pathology in tumor nephrectomy specimens: predicting the risk of progressive renal failure. Am J Surg Pathol 2006, 30:575-584.
83. Huang W.C., Levey A.S., Serio A.M., et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006, 7:735-740.
84. Lau W.K., Blute M.L., Weaver A.L., et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000, 75:1236-1242.
85. McKiernan J., Simmons R., Katz J., et al. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology 2002, 59:816-820.
86. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
87. Huang W.C., Elkin E.B., Levey A.S., et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors-is there a difference in mortality and cardiovascular outcomes?. J Urol 2009, 181:55-61. [discussion: 61-2].
88. Hellenthal N.J., Underwood W., Penetrante R., et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010, 184:859-864.
89. Ansari J., Doherty A., McCafferty I., et al. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clin Genitourin Cancer 2009, 7:E39-E41.
90. Thomas A.A., Rini B.I., Stephenson A.J., et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009, 182:881-886.
91. Silberstein J.L., Millard F., Mehrazin R., et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int 2010, 106:1270-1276.
92. Simmons M.N., Ching C.B., Samplaski M.K., et al. Kidney tumor location measurement using the C index method. J Urol 2010, 183:1708-1713.
93. Kutikov A., Uzzo R.G. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009, 182:844-853.
94. Karakiewicz P.I., Suardi N., Jeldres C., et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008, 53:845-848.
95. Harshman L.C., Srinivas S., Kamaya A., et al. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol 2009, 6:338-343.
96. Bex A., Van der Veldt A.A., Blank C., et al. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol 2010, 49:520-523.
97. Cost N., Delacroix S., Sleeper J., et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 2011, 59(6):912-918.
98. Flanigan R.C. Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res 2004, 10:6335S-6341S.
99. Mani S., Todd M.B., Katz K., et al. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995, 154:35-40.
100. Fisher R., Coltman C. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1988, 108:518-523.
101. Muss H., Costanzi J., Leavitt R. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 1987, 5:286-291.
102. Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408-417.
103. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
104. Flanigan R., Salmon S. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
105. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966-970.
106. Flanigan R.C., Mickisch G., Sylvester R., et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004, 171:1071-1076.
107. Pantuck A.J., Zisman A., Dorey F., et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003, 97:2995-3002.
108. Vasselli J.R., Yang J.C., Linehan W.M., et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001, 166:68-72.
109. Han K., Pantuck A., Bui M., et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003, 61(2):314-319.
110. Slaton J., Perrotte P., Balbay M., et al. Reassessment of the selection criteria for cytoreductive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 2000, 163:70.
111. Wood C., Huber N., Madsen L., et al. Clinical variables that predict survival following cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol 2001, 165:184A.
112. Culp S.H., Tannir N.M., Abel E.J., et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. Cancer 2010, 116:3378-3388.
113. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
114. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-5428.
115. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
116. Szczylik C., Porta C., Bracarda S., et al. Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008, 26. [abstr 5124]. Available at:, Accessed December 9, 2011. http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/5124%3Fsid=ee6c06b3-e9fb-4158-a5e5-54d5bddbfe40.
117. Choueiri T.K., Xie W., Kollmannsberger C., et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011, 185:60-66.
118. Warren M., Venner P.M., North S., et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J 2009, 3:281-289.
119. Singer E.A., Srinivasan R., Bratslavsky G. Editorial comment. J Urol 2011, 185:66.
120. Margulis V., Wood C.G. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?. Eur Urol 2008, 54:489-492.
121. Margulis V., Wood C.G., Jonasch E., et al. Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Curr Oncol Rep 2008, 10:253-258.
122. Bex A., Van der Veldt A.A., Blank C., et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 2009, 27:533-539.
123. Lara P.N., Tangen C.M., Conlon S.J., et al. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol 2009, 181:512-516. [discussion: 516-7].
124. Rodríguez Faba O., Breda A., Rosales A., et al. Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma. Eur Urol 2010, 58:307-310.
125. Shuch B., Riggs S.B., LaRochelle J.C., et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008, 102:692-696.
126. Amin C., Wallen E., Pruthi R.S., et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008, 72:864-868.
127. Wood C.G., Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 2009, 115:2355-2360.
128. Patard J.-J., Thuret R., Raffi A., et al. Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol 2009, 55:237-239. [quiz: 239].
129. Powles T., Kayani I., Blank C., et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol 2011, 22:1041-1047.
130. Abel E.J., Culp S.H., Tannir N.M., et al. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 2011, 60(6):1273-1279.